Neuroblastoma is a paediatric malignancy that typically arises in early childhood, and is derived from the developing sympathetic nervous system. Clinical phenotypes range from localized tumours with excellent outcomes to widely metastatic disease in which long-term survival is approximately 40% despite intensive therapy. A previous genome-wide association study identified common polymorphisms at the LMO1 gene locus that are highly associated with neuroblastoma susceptibility and oncogenic addiction to LMO1 in the tumour cells 1 . Here we investigate the causal DNA variant at this locus and the mechanism by which it leads to neuroblastoma tumorigenesis. We first imputed all possible genotypes across the LMO1 locus and then mapped highly associated single nucleotide polymorphism (SNPs) to areas of chromatin accessibility, evolutionary conservation and transcription factor binding sites. We show that SNP rs2168101 G>T is the most highly associated variant (combined P = 7.47 × 10 −29 , odds ratio 0.65, 95% confidence interval 0.60-0.70), and resides in a super-enhancer defined by extensive acetylation of histone H3 lysine 27 within the first intron of LMO1. The ancestral G allele that is associated with tumour formation resides in a conserved GATA transcription factor binding motif. We show that the newly evolved protective TATA allele is associated with decreased total LMO1 expression (P = 0.028) in neuroblastoma primary tumours, and ablates GATA3 binding (P < 0.0001). We demonstrate allelic imbalance favouring the G-containing strand in tumours heterozygous for this SNP, as demonstrated both by RNA sequencing (P < 0.0001) and reporter assays (P = 0.002). These findings indicate that a recently evolved polymorphism within a super-enhancer element in the first intron of LMO1 influences neuroblastoma susceptibility through differential GATA transcription factor binding and direct modulation of LMO1 expression in cis, and this leads to an oncogenic dependency in tumour cells.
Neuroblastoma is a paediatric malignancy that typically arises in early childhood, and is derived from the developing sympathetic nervous system. Clinical phenotypes range from localized tumours with excellent outcomes to widely metastatic disease in which long-term survival is approximately 40% despite intensive therapy. A previous genome-wide association study identified common polymorphisms at the LMO1 gene locus that are highly associated with neuroblastoma susceptibility and oncogenic addiction to LMO1 in the tumour cells 1 . Here we investigate the causal DNA variant at this locus and the mechanism by which it leads to neuroblastoma tumorigenesis. We first imputed all possible genotypes across the LMO1 locus and then mapped highly associated single nucleotide polymorphism (SNPs) to areas of chromatin accessibility, evolutionary conservation and transcription factor binding sites. We show that SNP rs2168101 G>T is the most highly associated variant (combined P = 7.47 × 10 −29 , odds ratio 0.65, 95% confidence interval 0.60-0.70), and resides in a super-enhancer defined by extensive acetylation of histone H3 lysine 27 within the first intron of LMO1. The ancestral G allele that is associated with tumour formation resides in a conserved GATA transcription factor binding motif. We show that the newly evolved protective TATA allele is associated with decreased total LMO1 expression (P = 0.028) in neuroblastoma primary tumours, and ablates GATA3 binding (P < 0.0001). We demonstrate allelic imbalance favouring the G-containing strand in tumours heterozygous for this SNP, as demonstrated both by RNA sequencing (P < 0.0001) and reporter assays (P = 0.002). These findings indicate that a recently evolved polymorphism within a super-enhancer element in the first intron of LMO1 influences neuroblastoma susceptibility through differential GATA transcription factor binding and direct modulation of LMO1 expression in cis, and this leads to an oncogenic dependency in tumour cells.
Genome-wide association study (GWAS) efforts frequently identify highly statistically significant genetic associations within non-coding regulatory regions of the genome, but the underlying causal DNA sequence variations have only been identified in a few instances. A neuroblastoma GWAS has identified several disease susceptibility loci [1] [2] [3] [4] [5] [6] [7] , with the signal within the LIM domain only 1 (LMO1) locus at 11p15 (ref. 1), a transcriptional co-regulator containing two zinc finger LIM domains that nucleate and regulate transcription factor complexes, being most robust. The main members of the LMO gene family, LMO1-4, are all implicated in cancer including LMO1 and LMO2 translocations in T-cell leukaemia 8 , and we previously provided the first evidence that LMO1 was a bona fide neuroblastoma oncogene 1 .
Here, we sought to identify the causal polymorphism(s) driving the LMO1 genetic association with neuroblastoma susceptibility as a basis for understanding neuroblastoma initiation and addiction mechanisms.
We first performed fine mapping of associated germline SNPs and indels at the LMO1 gene locus by imputation to the 1000 Genomes Project for our European-American neuroblastoma GWAS 6 . This identified 27 SNPs with minor allele frequency (MAF) >0.01 and an association P < 1 × 10 −5 ( Fig. 1a and Extended Data Table 1 ). We further prioritized associated variants by evolutionary conservation, and by their regulatory potential inferred through neuroblastoma-specific DNase I hypersensitivity mapping and chromatin immunoprecipitation sequencing (ChIP-seq) from the ENCODE Consortium (Fig. 1b) . These data showed that the most significantly associated SNP at the LMO1 locus (rs2168101, odds ratio = 0.67, P = 4.14 × 10
−16
) resides within a highly conserved and active enhancer region inferred by DNase I sensitivity and p300 binding in the SKNSH neuroblastoma cell line (Fig. 1b) . Notably, we found no rare or common non-synonymous coding variants in LMO1 in a combined cohort of 482 unique neuroblastoma cases with germline whole-genome (n = 136), whole-exome (n = 222) and/or targeted DNA sequencing (n = 183) (see Extended Data Table 2 and Supplementary Data).
Because rs2168101 genotypes were imputed in our analyses (Extended Data Fig. 1 ), we next directly genotyped this SNP in 146 out of 2,101 European-American cases, and measured an 86% imputation accuracy (Supplementary Table 1 ). We additionally directly genotyped rs2168101 in two independent cohorts from the UK and Italy, with both showing robust replication (Table 1) . We did not observe replication in an independent African-American cohort. Notably, the protective T allele is common in Europeans (CEU HapMap: 28%) and East Asians (CHB+JPT HapMap: 32%), but is rare or absent in Africans, indicating recent expansion of the rs2168101 protective allele in non-African human populations. Meta-analysis demonstrated a combined association P = 7.47 × 10 −29 across 8,553 controls and 3,254 cases ( Table 1) . As causal SNPs driving GWAS associations may disrupt transcription factor binding at distal enhancers, we sought to identify candidate SNPs disrupting known JASPAR motifs candidate SNP rs2168101 resides in a highly conserved GATA-binding motif (5′ -A[G/T]ATAA-3′ , mammalian phastCons score = 100%) (Fig. 1b) . ENCODE transcription factor ChIP-seq confirmed GATA2 and GATA3 binding at the rs2168101 GATA motif in the neuroblastoma cell lines SKNSH and SHSY5Y, which are G/G homozygous, thereby preserving the GATA motif (Fig. 1b) . No other associated variant showed this unique combination of evolutionary conservation, active enhancer localization, and disruption of a transcription factor binding motif, including the sentinel SNP rs110419 (P = 1.17 × 10 −13 ) from our original report 1 
.
To test for the possibility of multiple statistical signals or enhancers not marked by conservation or p300 at the LMO1 locus, we repeated association testing conditional on imputed rs2168101 genotypes and observed no significant variants after multiple test correction (most significant variant: rs34544683, nominal P = 9.0 × 10 −4
, Bonferroni P = 1; Extended Data Fig. 2a ). To test whether the rs2168101 signal can be equally captured by other variants, we also performed reciprocal association tests for rs2168101 conditioned on all 27 other SNPs within 1.5 megabases (Mb) of LMO1 passing thresholds MAF > 0.01 and nominal P < 1 × 10 −5 . Notably, rs2168101 remained significant across all conditional tests (worst-case nominal P = 2.6 × 10 −7 , Bonferroni P = 0.002; Extended Data Fig. 2b ). These results are consistent with a single underlying signal at the LMO1 locus, and re-affirm that rs2168101 is the single best causal SNP candidate, because its association with neuroblastoma cannot be accounted for by other variants.
We next sought to determine whether rs2168101 genotypes were associated with LMO1 expression by messenger RNA sequencing (mRNA-seq) of 127 primary high-risk neuroblastoma tumours. Genotyping rs2168101 yielded 102 G/G, 25 G/T and no T/T tumours (MAF = 9.8%). We observed significantly higher LMO1 expression in G/G versus G/T genotype tumours (t-test P = 0.028; Fig. 2a) . Notably, the absence of protective homozygous T/T genotypes in this high-risk neuroblastoma cohort is consistent with our previous observation that the risk alleles predispose to the high-risk phenotypic subset 1 (for clinical covariate associations, see Extended Data Table 3 ). Accordingly, the rs2168101 G/G genotype is highly associated with decreased neuroblastoma patient event-free (P = 0.0004) and overall (P = 0.0004) survival compared to G/T and T/T genotypes together in our European-American cohort (Extended Data  Fig. 3 ). Two cell lines with homozygous T/T or T/− genotypes expressed LMO1 at comparatively lower levels than cell lines containing the G allele (Extended Data Fig. 4a ).
GATA transcription factors mediate chromatin looping and facilitate long-range enhancer-promoter interactions to regulate target gene expression 10 . We therefore sought to confirm allelic imbalance of LMO1 transcripts (a hallmark of gene regulation in cis), which could result from differential GATA-binding caused by rs2168101. First, because the rs2168101 intronic SNP is not detectable by mRNA-seq, we identified the LMO1 exonic synonymous SNP, rs3750952, which can measure allelic expression in the heterozygous state. We identified 45 tumours with The neuroblastoma-associated region falls within a 40-kilobase (kb) haplotype block (grey box) in Europeans, encompassing the LMO1 3′-terminus. rs2168101 is the most associated variant and is moderately correlated (maximum r 2 = 0.52) with other variants. The sentinel SNP reported previously, rs110419, is also highlighted (#). b, Associated variants (P < 1 × 10
) are plotted with ENCODE tracks for neuroblastoma cell line SKNSH. Two SNPs, rs2168101 and rs7948497, were annotated 'enhancer SNPs' based on overlapping DNase peaks binding p300. The rs2168101 G>T SNP disrupts an evolutionarily conserved GATA transcription factor (TF) motif (5′-A[G/T]ATAA-3′ ). SKNSH has an rs2168101 = G/G genotype that preserves GATA binding, supported by ENCODE GATA3 ChIP-seq. Letter reSeArCH the necessary rs3750952 = C/G genotype, and then directly genotyped rs2168101 (G/G = 33, G/T = 12, T/T = 0) in this panel. By mRNA-seq, there was greater allelic imbalance in 12 tumours that were heterozygous for rs2168101 (G/T) than in 33 homozygous tumours (rs2168101 = G/G; t-test P < 0.0001; Fig. 2b ). We next used targeted sequencing of nuclear-enriched nascent RNAs in four neuroblastoma cell lines (G/G = 1, G/T = 2, T/T = 1) to provide direct ascertainment of allele-specific expression at rs2168101. In both heterozygous lines, we observed allelic imbalance that significantly favoured the risk G allele over the protective T allele (Fig. 2c) . Collectively, these results indicate that the intact GATA motif at rs2168101 results in significantly higher LMO1 expression levels than the TATA coded by the alternative allele. Allelic imbalance of LMO1 was not driven by somatic DNA alterations (for example, loss of heterozygosity) that could affect allelic dosage (Extended Data Fig. 4b ).
Examination of neuroblastoma transcriptome data for 127 primary tumours showed that GATA2 and GATA3 are overexpressed compared to other members of the GATA transcription factor family (Extended Data Fig. 5a ), and that GATA3 is the most highly expressed. Additionally, protein immunoblotting showed that GATA3 is uniformly highly expressed in neuroblastoma cell lines, while LMO1 is highly expressed in the G/G (SKNSH and SHSY5Y), G/− (KELLY) and G/T (IMR32) cell lines, but only barely detectable in the BE2C cell line that lacks a G allele at the rs2168101 locus (Extended Data Fig. 5b ). We therefore performed ChIP-seq using a GATA3 antibody in neuroblastoma cell lines, and observed robust GATA3 binding at rs2168101 in lines containing the G allele (SHSY5Y, KELLY, BE2 and NGP) but not in a line containing only a T allele (BE2C; Fig. 3a ). We then specifically considered GATA3 ChIP-seq reads overlapping rs2168101, and we observed strong preferential binding to the G allele in the G/T ; NGP: 1.00 G-allele fraction from 6 reads, 95% confidence interval: 0.54-1.00, binomial P = 0.03). c, Normalized ChIP-seq signal for H3K27ac at rs2168101. d, Ranked H3K27ac signal across all enhancers in MYCNamplified KELLY and BE2C lines. Super-enhancers associate with key neuroblastoma genes, highlighted on the curve. There is an LMO1-associated superenhancer in G-allele-containing lines SHSY5Y, KELLY and BE2, but not in BE2C, which lacks the G allele. e, Luciferase reporter assay for LMO1 enhancer region. The risk G allele preserved enhancer activity (t-test P = 0.002 across n = 4 independent clones, each with n = 5 technical replicates), whereas the protective T allele was indistinguishable from empty vector. f, Left, protein blots for GATA3, LMO1 and tubulin in SHSY5Y cells treated with control (siControl) short interfering RNAs (siRNAs), or with siRNAs targeting GATA3 (siGATA3-1 and siGATA3-2), at 72 h post-treatment. Right, cell counts for cell lines SHSY5Y, KELLY, KELLY stably overexpressing control vector (EV) and KELLY with forced LMO1 overexpression (LMO1-1 and LMO1-2) treated with siRNAs at 72 h posttransfection (see Extended Data Fig. 7 for complete growth curves). Rescue of suppressed cell growth after GATA3 depletion by forced LMO1 expression was observed at 72 h. Error bars denote ± s.e.m. *P < 0.05, * *P < 0.001 by t-test. n = 3 independent transfections, n = 9 technical replicates.
heterozygous
) and NGP (1.00 G-allele fraction from 6 reads, 95% confidence interval: 0.54-1.00, binomial test P = 0.03; Fig. 3b) .
Acetylation of histone H3 at lysine 27 (H3K27ac) is a hallmark of active enhancers 11 , and ChIP-seq analysis of SHSY5Y (G/G; not MYCN amplified), KELLY (G/−; MYCN amplified), BE2 (G/T; MYCN amplified) and NGP (G/T; MYCN amplified) neuroblastoma cells showed extensive H3K27 acetylation in the first intron of LMO1 across rs2168101, which was not observed in BE2C (T/− ; MYCN amplified; Fig. 3c ). This region is classified as a super-enhancer in G-allelecontaining lines SHSY5Y, KELLY and BE2 based on enhancer clustering and especially high H3K27ac signal (NGP was just below the threshold; see Methods), a pattern also observed for other known oncogenes and tumour suppressor genes in this disease 12 ( Fig. 3d and Extended Data Fig. 6a) . No super-enhancer was observed in BE2C or Jurkat T-ALL cells that also express LMO1 (ref. 13) , or in other non-neuroblastoma tissues from ENCODE ( Fig. 3d and Extended Data Fig. 6b, c) . These results are consistent with recent evidence that disease-associated SNPs frequently affect enhancers that are specific to disease-relevant cell lines and tumour histology, and control developmental stage and tissuespecific gene expression 12, [14] [15] [16] [17] [18] . We next performed luciferase reporter assays to measure the effect of rs2168101 alleles on enhancer activity. HEK293T cells transfected with constructs containing the risk G allele demonstrated 30-300-fold higher normalized luminescence compared to the T allele (t-test P = 0.002, Fig. 3e ), whereas luciferase activity of the T allele was not significantly different from empty vector, indicating that the intact GATA motif is required for robust enhancer activity. Finally, knockdown of GATA3 in SHSY5Y and KELLY cells resulted in both decreased LMO1 protein levels and suppression of cell growth that was rescued by LMO1 overexpression (Fig. 3f and Extended Data Fig. 7) , indicating the central role of GATA3 in regulating LMO1 expression levels in neuroblastoma.
Taken together, these data demonstrate the underlying molecular mechanism for a highly robust genetic association to neuroblastoma, mediated by a single common causal SNP rs2168101 that disrupts a GATA transcription factor binding site within a tissue-specific super-enhancer element. The rarity or absence of the protective allele in African populations and its relative depletion in African-Americans may partially explain the more aggressive clinical course in AfricanAmerican children 19 . Moreover, this work further confirms the utility of association studies to define clinically relevant oncogenic pathways. Finally, the dependence of neuroblastoma cells on super-enhancermediated LMO1 expression provides another potential mechanism for the sensitivity of these tumours to inhibitors of the transcriptional machinery such as CDK7 and BET bromodomain proteins 14, 16 , demonstrating the potential of translating basic mechanistic insights of tumour initiation towards novel therapeutic strategies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
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MeThOdS
No statistical methods were used to predetermine sample size. Genotype imputation and association testing. A primary European-American cohort of 2,101 cases and 4,202 matched controls were assayed with Illumina HumanHap550 v1, Illumina HumanHap550 v3, and Illumina Human610 SNP arrays as previously described 6 . Genotypes were phased using SHAPEIT v2.r790 and data from 1000 Genomes phase 1 version 3. Subsequently, imputation was performed using IMPUTE2 v2.3.1 for all SNPs and indel variants annotated in the 1000 Genomes phase 1 version 3. Testing for association with neuroblastoma under an additive genetic effect model was performed using the frequentist likelihood score method implemented in SNPTEST v2.4.1. Genotypes for a previously described African-American cohort of 365 cases and 2,491 controls 20 were imputed and tested for neuroblastoma association using the same analytic pipeline. Statistical adjustment for gender was performed in both cohorts. For population stratification adjustment, the first 20 multidimensional scaling (MDS) components were included as covariates in the European-American cohort, while a measure of African admixture as estimated by the ADMIXTURE software program was used in the African-American cohort. Manhattan plots of SNP position and statistical significance were generated using LocusZoom software. Linkage plots were generated by Haploview software based on HapMap CEU individuals (version 3, release 2) using default settings. All research subjects or their guardians provided informed consent for research, and all institutions involved in this research had regulatory approval for human subjects research. Prioritization of candidate causal variants. All SNPs and indels reported in the 1000 Genomes phase 1 version 3 data were considered as candidate causal variants and were ranked based on a combination of (1) neuroblastoma association in the primary European-American cohort, (2) evolutionary conservation, (3) DNase I hypersensitivity, and (4) transcription factor binding motif matching. Neuroblastoma association in European-Americans was evaluated as described above. Conservation scores were computed as the average of the phastCons46way-Placental UCSC conservation track score for all bases from the −10 position to the +10 position surrounding each candidate variant. A DNase I hypersensitivity score was calculated by counting the number of sequencing tags from the −100 position to the +100 position around each candidate variant in ENCODE data for the neuroblastoma cell line, SK-N-SH. Position weight matrices representing transcription factor binding motifs were obtained from the JASPAR database, and candidate binding sites were identified by scanning the hg19 human reference genome using the MATCH-TM algorithm with a matrix similarity score (mSS) threshold of 0.90. Neuroblastoma association replication and meta-analysis for rs2168101. We replicated the association of rs2168101 with neuroblastoma by direct genotyping of rs2168101 in independent Italian (cases = 420, controls = 751) and UK cohorts (cases = 369, controls = 1,109). Meta-analysis across the European-American, African-American, Italian and UK cohorts was performed using the inverse variance method provided in the METAL software program. Beta values (log-odds) and standard errors generated by SNPTEST, as described above, were used as input. Survival analysis. We compared both overall survival and event-free survival over a 10-year follow-up period between G/G versus G/T and T/T rs2168101 genotypes in a case-case comparison between neuroblastoma patients from the EuropeanAmerican cohort. Because rs2168101 genotypes were imputed in this cohort, the most-probable genotype predicted by IMPUTE2 was used for each patient. In the event of insufficient follow-up, all data was right censored. Cox proportional hazard modelling was performed using 20 MDS components to account for population stratification, in addition to MYCN amplification status, as covariates. All statistical analysis and generation of Kaplan-Meier plots was performed in R using the CRAN repository package, 'survival' . Total and allele-specific expression analysis. Total and allele-specific RNA expression analysis was performed based on poly-A-enriched RNA-sequencing data from 127 primary neuroblastoma tumours sequenced through the TARGET project. RNA-seq reads were aligned to the hg19 human reference genome using the STAR aligner (v2.4.0b). Aligned reads were assigned to RefSeq genes using HTSeq (v0.6.1) and normalized to RPKM for total gene expression measurements. DNA genotypes for rs2168101 were obtained either through matched whole-genome sequencing (n = 69) or targeted genotyping assays (n = 58 additional tumours). DNA genotypes for rs3750952 were obtained through either matched wholegenome or whole-exome sequencing.
Allele-specific RNA expression analysis was performed from a subset of 45 primary neuroblastoma tumours (out of 127) with the necessary synonymous exonic SNP genotypes (rs3750952 = C/G) to enable measurement of allelic expression by mRNA-seq. As a readout for allelic imbalance of rs3750952, we computed allelic fractions as min(C, G)/(C + G), since phasing between rs3750952 and rs2168101 alleles in each tumour was unknown. Statistical comparison between the two groups was performed by two-sided Welch's t-test, comparing 12 tumours heterozygous for rs2168101 (G/T) to the remaining 33 tumours that were homozygous for rs2168101 (G/G) as controls. DNA genotyping for rs2168101 was performed by whole-genome sequencing or a directed genotyping assay, whereas DNA geno typing for rs3750952 was determined from TARGET whole-exome or wholegenome sequencing. Where possible, integrity of sample matching was verified by measurement of genome-wide genotype concordance. All genotypes are reported with respect to the minus strand of the human reference genome, hg19.
To measure allele-specific expression directly at the intronic SNP we first purified the nuclear RNA fraction using the Cytoplasmic and Nuclear RNA purification Kit (Norgen Biotek, 21000) from four neuroblastoma cell lines (SNP rs2168101: SHSY5Y = G/G; NLF = G/T; NGP = G/G; NB1643 = T/T). Ion AmpliSeq Designer v3.4.3 (Life Technologies White Glove service) was used to design amplicons targeting the intronic SNP rs2168101 and three additional exonic SNPs in linkage disequilibrium. Custom AmpliSeq libraries were prepared in triplicate for each cell line, indexed, pooled and sequenced using an Ion 318 Chip on a Personal Genome Machine (Life Technologies). Reads were aligned to the hg19 reference genome and a synthetic genome showing the alternate allele at SNP rs2168101 at hg19 chr11:8255408 to account for any alignment bias. Highquality mapped reads containing the reference G allele or alternative T allele were counted and tested for significant deviation from 50:50 expression using a twosided one-sample t-test (null hypothesis that allele fraction = 0.50) across three experimental replicates. Primer pair sequences: rs1042359 forward: 5′ -GTGTGG GAGACAAAUTCTTCCUGA-3′, reverse: 5′-GCCGGGCGUTACTGAACUT-3′; rs3750952 forward: 5′-CGCAAGAUCAAGGACCGCTAUC-3′, reverse: 5′-GATGAGGTUGGCCTTGGTGUA-3′; rs2168101 forward: 5′-CCUT TCCUGAAGGAGCGCAAA-3′, reverse: 5′-CACTTTCCATUAAGGAGAT AGCAUCCC-3′; rs204929 forward: 5′ -CAAUCTAGGTUAAGAGCCGGACAA G-3′, reverse: 5′-GTGUCCAGCCGCAGCUA-3′ . Reporter assays. Primers were designed to clone a 553-bp genomic region (hg19, chr11:8255155-8255707) surrounding the candidate SNP rs2168101 at the GATA transcription factor binding site from neuroblastoma cell lines SKNSH (G/G) and matching site of BE2C (T/− ). The cloned region did not contain other statistically significant SNPs at the LMO1 locus. The primers were designed to introduce sequences for restriction sites 5′ -XhoI and 3′ -BglII, which are present in the MCS of pGL4.26[luc2/minP/Hygro] (Promega, E8441). XhoI/BglII restriction enzyme digested fragments were sequence verified, gel purified, ligated into pGL4.26[luc2/ minP/Hygro], transformed into One Shot TOP 10 chemically competent cells (Life Technologies, C4040-10) and grown on LB plates containing 50 μ g ml −1 ampicillin overnight at 37 °C. Colonies positive for the vector containing the insert were grown in 50 ml LB broth containing 50 μ g ml −1 ampicillin and plasmids were purified using a Qiagen Plasmid Midi Prep Kit (Qiagen, 12143). Transfection into HEK293 cells which were approximately 50% confluent was accomplished using Fugene 6 Transfection reagent (Promega E2691) at a 3 μ l:1 μ g fugene:DNA ratio. Cells underwent selection in 150 μ g ml −1 Hygromycin B (Mediatech, 30-240-CR) and individual colonies were picked and grown, and genotypes of constructs were confirmed by fragment size and Sanger sequencing. Subsequently, HEK293 + 553 bp insert cells and HEK294 + vector only cells were grown in 96-well optical plates. On day 2, the cells were transiently fugene transfected with the Renilla expression control vector pGL4.74[hRLuc/TK] (Promega, E6921) at a 1:500 dilution with respect to the luciferase vector. Luciferase assays were carried out 48 h after Renilla transfection using Dual Luciferase Reporter Assay System (Promega, E1910) with read-outs performed on a Dual Injector System for GloMax-Multi Detection System (Promega, E7081). Luciferase expression was normalized to Renilla expression. All reporter assays were performed in quintuplicate (five technical replicates each) across the experimental conditions: (1) HEK293T, (2) HEK293T with empty vector, (3)-(6) four independent clones of HEK293T with T allele construct, and (7)- (10) four independent clones of HEK293T with G allele construct. Results were averaged across technical replicates, normalized to empty vector, and reporter activities for T allele versus G allele clones (four biological replicates each) were analysed by two-sided Welch's t-test. Construct risk allele (G):  GTAGGGGTTGGAGTTCAGCCTGTTTCCCCTCCAATGTTGTTCCCCC  CACATCCTGAGACTTAGGGGTGACCCTGGGTTGAGTGGACTGGTTTA  TTCTGCTGGGCCCAGCGCATGCATCTGAGTGTGTGCCCAGGCGTGCG  TGTCGGCGCAAACATCATCCATTGTGAAATATCAGTGTTTTCATGGGT  GAGTAGTAATTACTGGGTAATGCTTTAAAACCTTTCCTGAAGGAGCGC  AAAGCCATTTTTTTCTAAAGTCAGGAGTACATTAAAAGGATTACCATG  TAGATTTGATTTTTAGATAACACTAAAATGGATCCCAAATGGACTTCA  GCAAAGGGATGCTATCTCCTTAATGGAAAGTGCATGGCCCGAGGCTC  AGGTCCCAGAGCCAGGCTGGGGAAGGAGGGAGGGAAGAGGTGTCTG  CAGGGGGGCAGGCTGGCAGATTGGGTGGGGGCTAGGTGGGAATGGG  GAAGGCAGAGCAGGAGGGAGGGCCTGGACCCTGTGGGGAGCTTATC  CCTCCATCTGGGGAGCAGGAGACTACAGAGCCCCT. . ChIP-seq processing. Reads were aligned to build hg19 of the human genome using bowtie with parameters -k 2 -m 2 -e 70 -best and -l set to the read length 24 . For visualization in the UCSC genome browser in Fig. 3a, c and Extended Data Fig. 6 (ref. 25) , WIG files were created from aligned ChIP-seq read positions using MACS 1.4.2 with parameters -w -S -space = 50 -nomodel -shiftsize = 200 to artificially extend reads to be 200 bp and to calculate their density in 50-bp bins 26 . Read counts in 50-bp bins were then normalized to the millions of mapped reads, giving reads per million values. ChIP-seq allele specificity analysis. To determine preferential ChIP-seq coverage of one allele, which implies preferential binding of protein to one allele versus another, we counted the reads at rs2168101 using samtools mpileup 27 . By using the aligned reads described above, this gave us a count of reads with a given base at this position. The fraction of reads with the risk allele versus the protective allele is reported in Fig. 3b . Statistical tests for preferential allelic binding were performed by two-sided binomial test. Enriched regions. Regions enriched in ChIP-Seq signal were identified twice using MACS with corresponding control and parameters -keep-dup = all and -p 1e-9 or -keep-dup = 1 and -p 1e-9. Super-enhancers in SHSY5Y and KELLY were identified using ROSE (https://bitbucket.org/young_computation/rose) 18, 28 with modifications based on ref. 14. In brief, peaks of H3K27ac were identified using MACS as described above and their union was used as constituent enhancers. These peaks were stitched computationally if they were within 12,500 bp of each other, although peaks fully contained within ±2,000 bp from a RefSeq promoter were excluded from stitching. These stitched enhancers were ranked by their H3K27ac signal (length × density) with input signal in the corresponding region subtracted. Superenhancers were separated from typical enhancers by geometrically determining the point at which the line y = x is tangent to the curve of stitched enhancer rank versus stitched enhancer signal. Those stitched enhancers above this point are considered super-enhancers.
To account for the known focal amplification of the MYCN locus in KELLY, BE2, BE2C and NGP neuroblastoma cells, which contain enhancers, we modified our pipeline slightly. Because MACS is insensitive for the identification of peaks in focally amplified DNA, we identified peaks of H3K27ac versus input using MACS2 callpeak (https://pypi.python.org/pypi/MACS2) with parameters -broad -keep-dup = 1 -p 1e-9 and -broad -keep-dup = all -p 1e-9. The union of these MACS2 calls was used as constituent enhancers for ROSE with the remaining parameters as described above. For Fig. 3d , most of the curve represents the analysis performed using MACS-identified constituents; the rank and signal of the MYCN-associated enhancer comes from this MACS2-identified set of constituents to remain consistent with the conclusions and methods as previously described 14 . The curve output from the MACS-identified enhancers was vertically compressed and a point representing the signal of the MYCN-associated super-enhancer from the MACS2-identified enhancers was added in Illustrator. Super-enhancers were assigned to the single expressed RefSeq transcript whose transcription start site was nearest the centre of the stitched region. Expressed genes were in the top 2/3 of RefSeq transcripts ranked by their promoter (transcription start site ± 500 bp) H3K27ac signal determined by bamToGFF (https://github.com/BradnerLab/ pipeline) with parameters -e 200 -m 1 -r -d. Clone cell generation. LMO1 cDNA was amplified from pcDNA3-LMO1 and subcloned into the XhoI and NotI site of the lentiviral vector pOZ-FHN. Lentivirus expressing FH-LMO1 was propagated in HEK293T cells by cotransfection with psPAX2 and pMD2.G plasmids (adgene) using FUGENE 6 (Roche) by standard methodologies 29 . Viral supernatant was recovered and KELLY cells were infected with lentivirus expressing FH-LMO1 or empty vector alone, as previously described 13 . Cells were sorted for expression of the IL2R, and positive expression was used to establish single cell clones. Expression of FH-LMO1 was assessed by western blotting as above to confirm overexpression. siRNA and growth assays. SHSY5Y, KELLY and KELLY clone cells were reverse transfected with 100 nM concentrations of either non-targeted (control siRNA-1) or GATA3-targeted siRNA-1 or -2 (Ambion) for 6 h with lipofectamine 2000 (1:1,000) in Optimem I before being replated into growth assays in normal RPMI growth media. Cells (2 × 10 5 ) were replated in triplicate for counting at 24, 48 and 72 h post-transfection by manual hemocytometry. Cells (5 × 10 5 ) were replated for protein lysates at the same time points. All experiments were repeated in triplicate, with a technical replicate number of 9 for all cell growth assays as described 30 . Statistical tests were performed by two-sided Welch's t-test. Data access. GWAS and sequencing data used for this analysis are available in dbGaP under accession phs000124 and phs000467. The tumour genomics data are also available through the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) data matrix portal (http://target.nci.nih.gov/ dataMatrix/TARGET_DataMatrix.html). Data generated through the ENCODE project including DNase I hypersensitivity sequencing and ChIP-sequencing data were obtained from ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/ encodeDCC/. Aligned sequencing read (bam) files were used as provided from the FTP site. The mammalian evolutionary conservation track representing 46 mammalian species (phastCons46wayPlacental) was obtained from the UCSC Table  Browser http://genome.ucsc.edu/cgi-bin/hgTables?command= start. JASPARannotated transcription factor binding site position frequency matrices were obtained from http://jaspar.genereg.net/html/DOWNLOAD/JASPAR_CORE/ pfm/nonredundant/pfm_all.txt. New ChIP-seq data sets generated in this study are available under super series GSE65664.
Letter reSeArCH extended data Table 2 | Clinical characteristics for patients in referenced sequencing data sets * There is an overlap of 59 neuroblastoma patients with both whole-exome and whole-genome sequencing. Patients with targeted sequencing are all unique and do not overlap with whole-exome or whole-genome cases, yielding 482 unique patients with exonic DNA sequencing of LMO1. †International Neuroblastoma Staging System (INSS).
